European Psychiatry - Volume 33 - March 2016

301 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S297
Conclusions In this young, newly diagnosed schizophrenia pop-
ulation, the number of hospitalizations following PP initiation was
low. Main reason to initiate PP was clinicians favoring LAT over
oral antipsychotic treatment for relapse prevention or due to par-
tial/non adherence with previous oral treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW520
Real-world paliperidone palmitate
data from acute units: The SHADOW
study
E. Parellada ∗, M. Bioque , B. Herrera , M. García-Dorado
1 Hospital Clínic de Barcelona, Unitat d’Esquizofrènia Clínic,
Barcelona, Spain
2 Janssen-Cilag S.A., Medical Department, Spain
∗ Corresponding author.
Introduction There is an increasing interest in understanding
how antipsychotic treatments work in a real-world-setting. This
is especially important with long-acting-antipsychotics, where
explanatory trials may not always represent the real-world-
population. Observational studies and pragmatic-clinical trials
could provide additional information about new therapies, which
could inform decision-making processes.
Objectives To assess the effectiveness of Paliperidone-
Palmitate(PP) in an acute setting within real-world-conditions.
Functionality, satisfaction with treatment and pattern of use were
also evaluated.
Methods An observational, prospective 6-week follow-up study
was performed in acute units including adult patients with acute
exacerbation of schizophrenia that started treatment with PP. Data
were collected from initiation of PP until week-6 (or patient’s dis-
charge if earlier). Clinical-Global Inventory-Severity (CGI-S) was
used to assess effectiveness as well as changes in illness severity.
Other outcomes included total score on the Personal and Social Per-
formance scale (PSP), patient-satisfaction with medication (MSQ)
and tolerability. Student’s-t tests were used to assess changes from
baseline in CGI-S and PSP.
Results Two hundred and eighty patients were included in the
analysis (mean age: 40.5 ± 12.2 [SD] years). A significant decrease
in mean (SD) CGI-S score between baseline (4.7 [0.9]) and end-
point (3.3 [0.9]) (P< 0.0001) was observed. (Note that 21% of
patientswere dischargedonPP-monotherapy). Patient-functioning
also significantly improved from baseline to endpoint (P < 0.0001).
Seventy-four percent of patients were satisfied (measured by
MSQ) at the end of follow-up. Anticholinergic-treatment was less
frequent for PP discharged on monotherapy vs. not monother-
apy (12.5% vs 21.2% respectively). Overall, PP was well-tolerated.
Twenty-five AEs were reported in 20 patients (incidence 7.1%). No
serious AEs occurred.
Conclusions These results support the effectiveness and tolera-
bility of PP in an acute setting under daily-clinical-practice with
good acceptance by patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW521
Reducing cardiovascular risk in
non-selected outpatients with
schizophrenia: A 2.5-year programme
conducted in a real-life setting
P. Hjorth ∗, P.M. Jørgensen , A. Kynde
1 Aarhus university hospital, mental health center- psychiatric
hospital, Randers, Denmark
2 Odense university hospital, department of psychiatry, Odense,
Denmark
3 Aarhus university hospital- Risskov, department of organic mental
disorder and emergency Ward, Aarhus, Denmark
∗ Corresponding author.
Introduction Patients with schizophrenia have increased somatic
morbidity and increased mortality. Knowledge of how to integrate
prevention and care of somatic illnesses into the treatment of psy-
chiatric patients is required.
Objectives Forty-seven patients diagnosed with schizophrenia
participated in the programme (mean age: 33.3 years, SD: 11.9).
Aims To investigate whether a 2.5-year interventional pro-
gramme to improve physical health is effective.
Method The intervention consistedof healthpromotion activities
focusing on the patients’ health, not their diseases. The patients’
physical health parameters were intensely monitored and each
patient received individual guidance on healthy food and on how
to live a physically active life.
Results Extensive problems with obesity, especially among the
women, were observed, and low level of physical activity among
the patients was demonstrated. The included patients were in a
high risk of developing cardio vascular diseases and diabetes type 2.
The main outcomes were reduction in waist circumferences and in
consumption of soft drinks and an increase in coffee drinking. Fur-
thermore, an increase in time spent on moderate and light physical
activities was observed. The patients showed great interest in the
programme, and it was unproblematic getting the patients to par-
ticipate in the entire programme. Moreover, theywillingly followed
the health guidance and achieved a healthier life.
Conclusions The intervention seems relevant and manageable
in an outpatient setting. The results are promising in the ongo-
ing process of improving physical health among patients with
schizophrenia. We recommend implementation of the programme
in daily practice.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW522
A mirror image study of the utility of
long acting aripiprazole
R. Hodgson ∗ ladakatti , N. Kataria , T. Saravanappa ,
D. Brittany
Lyme Brook Centre, Psychiatry, Stoke-on-Trent, United Kingdom
∗ Corresponding author.
Aims and background Ablify Maintena (AM) is a long acting injec-
tion of aripiprazole that receivedmarketing authorisation in the UK
in January 2014. It is costly compared to first generation antipsy-
chotics (FGAs) LAIs and there are no robust trials comparing AM
with FGAs. We examined the effectiveness and use of AM in a
mental health trust.
Methods We identified all patients prescribed AM in North
Staffordshire (population: 470,000) since launch and examined
records for demography, diagnosis, bed and medication use. We
examined the effectiveness of AM using a mirror image design.
Results Thirty patients received AM in a time frame allowing a 1-
year follow-up. Sixty-nine percentweremale and themean agewas
39 years. Over half were detained under the 1983 Mental Health
Act and 30% were inpatients on a psychiatric intensive care unit
when AMwas started. Twenty-eight patients had a psychotic diag-
nosis. There was a significant reduction in bed occupancy (63 v 6
days, P = 0.0001) and admissions (1.6 v 0.5, P = 0.0001). The median
dose was 400 mg. Lack of effectiveness/poor adherence with prior
treatments were the main reason for starting AM in 84%. Eighty-six